Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 May;33(5):495-8.
doi: 10.1097/INF.0000000000000143.

Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children

Quirine Fillekes  1 , Lindsay Kendall, Sabrina Kitaka, Peter Mugyenyi, Philippa Musoke, Milly Ndigendawani, Mutsa Bwakura-Dangarembizi, Diana M Gibb, David Burger, Ann Sarah Walker; ARROW Trial Team
Collaborators, Affiliations
Free PMC article
Randomized Controlled Trial

Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children

Quirine Fillekes et al. Pediatr Infect Dis J. 2014 May.
Free PMC article

Abstract

Data on zidovudine pharmacokinetics in children dosed using World Health Organization weight bands are limited. About 45 HIV-infected, Ugandan children, 3.4 (2.6-6.2) years, had intensive pharmacokinetic sampling. Geometric mean zidovudine AUC0-12h was 3.0 h.mg/L, which is higher than previously observed in adults, and was independently higher in those receiving higher doses, younger and underweight children. Higher exposure was also marginally associated with lower hemoglobin.

PubMed Disclaimer

Conflict of interest statement

ARROW was funded by the UK Medical Research Council and the UK Department for International Development (DfID). Drugs were provided by GlaxoSmithKline who also provided funding for this PK study and conducted the pharmacokinetic drug concentration assays. The authors have no other funding or conflicts of interest to disclose.

Figures

FIGURE 1.
FIGURE 1.
Mean zidovudine concentrations, exposure, age and hemoglobin at pharmacokinetic sampling. A) Mean zidovudine plasma concentrations. B) Relationship between zidovudine exposure [area under the concentration–time curve 0–12 hours postdose (AUC0–12h)] and age (years) at pharmacokinetic sampling. C) Relationship between zidovudine clearance (CLF/kg) and age (years) at pharmacokinetic sampling. D) Relationship between hemoglobin and zidovudine exposure [area under the concentration–time curve 0–12 hours postdose (AUC0–12h)] at pharmacokinetic sampling. Note: In panel A), children receiving 450 mg daily received 300 mg zidovudine in the morning and are included in this group. In panel B), fitted effect of age is shown for a child with median weight-for-age (−1.09) and median dose (242 mg/m2). Points demonstrate the relationship between age and dose which is adjusted for within the multivariable model.
See this image and copyright information in PMC

References

    1. World Health Organisation. Antiretroviral therapy of HIV infection in infants and children: towards universal access. Recommendations for a public health approach: 2010 revision. Geneva, World Health Organisation; 2010. Available at: http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html. Accessed: December 15, 2011. - PubMed
    1. EMA. Combivir tablet; Summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Info.... Accessed February 12, 2012.
    1. Musiime V, Kendall L, Bakeera-Kitaka S, et al. ARROW Trial team. Pharmacokinetics and acceptability of once-versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. Antivir Ther. 2010;15:1115–1124. - PubMed
    1. Balis FM, Pizzo PA, Eddy J, et al. Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. J Pediatr. 1989;114:880–884. - PubMed
    1. Bergshoeff AS, Fraaij PL, Verweij C, et al. Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children. J Antimicrob Chemother. 2004;54:1152–1154. - PubMed

Publication types